Lucid Diagnostics Inc
LUCD1.130USD
+0.010+0.89%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
147.94MMarket Cap
LossP/E TTM
More Details of Lucid Diagnostics Inc Company
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard and EsoCheck. EsoGuard is a bisulfite-converted next generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. It is also developing EsoCure, is an Esophageal Ablation Device, which is a technology that allows a clinician to treat dysplastic BE.
Lucid Diagnostics Inc Info
Ticker SymbolLUCD
Company nameLucid Diagnostics Inc
IPO dateOct 14, 2021
CEOAklog (Lishan)
Number of employees72
Security typeOrdinary Share
Fiscal year-endOct 14
Address360 Madison Avenue
CityNEW YORK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code10017
Phone12129494319
Websitehttps://www.luciddx.com/
Ticker SymbolLUCD
IPO dateOct 14, 2021
CEOAklog (Lishan)
Company Executives of Lucid Diagnostics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Lishan Aklog, M.D.
Dr. Lishan Aklog, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.54M
+5.11%
Mr. Dennis M. Mcgrath
Mr. Dennis M. Mcgrath
Chief Financial Officer
Chief Financial Officer
1.39M
+5.69%
Mr. Dennis Matheis, CPA
Mr. Dennis Matheis, CPA
Independent Director
Independent Director
562.80K
+21.61%
Mr. Ronald M. (Ron) Sparks
Mr. Ronald M. (Ron) Sparks
Independent Director
Independent Director
504.38K
+155.43%
Dr. James L. Cox
Dr. James L. Cox
Independent Director
Independent Director
282.12K
-6.47%
Mr. Stanley N. Lapidus
Mr. Stanley N. Lapidus
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
214.39K
-8.34%
Dr. Jacque J. Sokolov, M.D.
Dr. Jacque J. Sokolov, M.D.
Independent Director
Independent Director
197.46K
-8.99%
Mr. John R. Palumbo
Mr. John R. Palumbo
Director
Director
47.86K
--
Ms. Debra J. White
Ms. Debra J. White
Independent Director
Independent Director
--
--
Mr. Shaun M. O'Neil
Mr. Shaun M. O'Neil
President, Chief Operating Officer
President, Chief Operating Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Lishan Aklog, M.D.
Dr. Lishan Aklog, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.54M
+5.11%
Mr. Dennis M. Mcgrath
Mr. Dennis M. Mcgrath
Chief Financial Officer
Chief Financial Officer
1.39M
+5.69%
Mr. Dennis Matheis, CPA
Mr. Dennis Matheis, CPA
Independent Director
Independent Director
562.80K
+21.61%
Mr. Ronald M. (Ron) Sparks
Mr. Ronald M. (Ron) Sparks
Independent Director
Independent Director
504.38K
+155.43%
Dr. James L. Cox
Dr. James L. Cox
Independent Director
Independent Director
282.12K
-6.47%
Mr. Stanley N. Lapidus
Mr. Stanley N. Lapidus
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
214.39K
-8.34%
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
1.16M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Dec 5
Updated: Fri, Dec 5
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
PAVmed Inc
29.65%
The Vanguard Group, Inc.
3.46%
Masters Capital Management, L.L.C.
3.05%
BlackRock Institutional Trust Company, N.A.
2.54%
Two Seas Capital LP
2.29%
Other
59.01%
Shareholders
Shareholders
Proportion
PAVmed Inc
29.65%
The Vanguard Group, Inc.
3.46%
Masters Capital Management, L.L.C.
3.05%
BlackRock Institutional Trust Company, N.A.
2.54%
Two Seas Capital LP
2.29%
Other
59.01%
Shareholder Types
Shareholders
Proportion
Corporation
29.65%
Hedge Fund
10.60%
Investment Advisor
8.53%
Investment Advisor/Hedge Fund
7.49%
Individual Investor
5.64%
Research Firm
1.07%
Bank and Trust
0.07%
Pension Fund
0.05%
Other
36.90%
Institutional Shareholding
Updated: Sun, Oct 5
Updated: Sun, Oct 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
126
22.24M
16.21%
+8.76M
2025Q2
95
49.62M
45.86%
+8.13M
2025Q1
87
48.55M
48.13%
+9.11M
2024Q4
72
40.61M
68.54%
+2.85M
2024Q3
67
37.54M
71.75%
+1.52M
2024Q2
80
37.13M
71.19%
+1.04M
2024Q1
96
36.05M
80.31%
-3.56M
2023Q4
96
34.89M
79.71%
-1.40M
2023Q3
97
35.04M
80.14%
-1.22M
2023Q2
93
35.02M
80.10%
-1.13M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
PAVmed Inc
31.30M
22.81%
--
--
Dec 06, 2024
The Vanguard Group, Inc.
4.13M
3.01%
+3.24M
+364.33%
Jun 30, 2025
Masters Capital Management, L.L.C.
2.73M
1.99%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.27M
2.38%
+3.24M
+11867.55%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.58M
1.15%
+1.27M
+420.28%
Jun 30, 2025
Aklog (Lishan)
1.47M
1.07%
-75.00K
-4.86%
Apr 22, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.02%
iShares Core S&P Total U.S. Stock Market ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Russell 2000 Value ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
iShares Micro-Cap ETF
Proportion0.02%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Lucid Diagnostics Inc?
The top five shareholders of Lucid Diagnostics Inc are:
PAVmed Inc holds 31.30M shares, accounting for 22.81% of the total shares.
The Vanguard Group, Inc. holds 4.13M shares, accounting for 3.01% of the total shares.
Masters Capital Management, L.L.C. holds 2.73M shares, accounting for 1.99% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.27M shares, accounting for 2.38% of the total shares.
Geode Capital Management, L.L.C. holds 1.58M shares, accounting for 1.15% of the total shares.
PAVmed Inc holds 31.30M shares, accounting for 22.81% of the total shares.
The Vanguard Group, Inc. holds 4.13M shares, accounting for 3.01% of the total shares.
Masters Capital Management, L.L.C. holds 2.73M shares, accounting for 1.99% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.27M shares, accounting for 2.38% of the total shares.
Geode Capital Management, L.L.C. holds 1.58M shares, accounting for 1.15% of the total shares.
What are the top three shareholder types of Lucid Diagnostics Inc?
The top three shareholder types of Lucid Diagnostics Inc are:
PAVmed Inc
The Vanguard Group, Inc.
Masters Capital Management, L.L.C.
PAVmed Inc
The Vanguard Group, Inc.
Masters Capital Management, L.L.C.
How many institutions hold shares of Lucid Diagnostics Inc (LUCD)?
As of 2025Q3, 126 institutions hold shares of Lucid Diagnostics Inc, with a combined market value of approximately 22.24M, accounting for 16.21% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -29.65%.
What is the biggest source of revenue for Lucid Diagnostics Inc?
In FY2025Q2, the -- business generated the highest revenue for Lucid Diagnostics Inc, amounting to -- and accounting for --% of total revenue.
